As a clinician who has discovered a new gene as the cause of a rare disease you can submit a Connection Application to the RDMM-Europe Clinical Advisory Committee (CAC). If approved, the Solve-RD Project Management Office will open a call for tender for Seeding Grant applications and starts searching for Model Organism Investigators with relevant expertise using the RDMM-Europe database. The Model Organism Investigators will be invited to submit a Seeding Grant application for functional studies of the respective gene.
Connection Applications can be submitted within specific deadlines (6x per year, deadlines will be announced on the Solve-RD website and via a newsletter to the Solve-RD consortium). Up to three Seeding Grants will be awarded per deadline. Clinicians will have the possibility to suggest Model Organism Investigators for the functional analyses.
The RDMM-Europe Scientific Advisory Committee (SAC) will review the submitted Seeding Grant applications. The clinician who submitted the Connection Application will be asked to establish a connection with the selected Model Organism Investigator. Following a successful connection, Clinician and Model Organism Investigator will be contacted by the Project Management Office to sign a Memorandum of Agreement. In addition, the model organism lab will sign a subcontract in order to receive the Seeding Grant of 20,000 EUR to functionally validate the new disease gene.
- Clinicians must be affiliated with a Solve-RD beneficiary or associated partner institution.
- Clinicians must not have a financial interest holding of more than 5% in a company proposed as an industry partner for research funding.
- Clinicians must confirm to have all relevant ethical approvals and patient consents in place.
The specific objectives of the Solve-RD brokerage service are to:
- provide functional validation of human genetic variants that cause disease;
- supplement clinical disease gene discoveries by generating functional data so as to get higher impact publications;
- develop insights into potential rationale for treatment (e.g. identification of candidate drug targets) via knowledge of a disease gene pathway; and
- establish longer term collaborations between basic scientists and clinicians that will lead to subsequent grant funding in support of outstanding basic and/or applied research.
Memorandum of Agreement
Clinicians who have submitted successful Connection Applications and Model Organism Investigators who are awarded a Seeding Grant will be expected to sign a Memorandum of Agreement (MoA) which sets out the ground rules and operative principles of the RDMM-Europe Network for investigators who wish to collaborate and receive funding.